Leukopak®, Frozen | StemExpress

Leukopaks®, Frozen

$3,300
In stock
SKU
Category: Research Products
Select SKU Size / Day Price
LE002.5C 2.5 billion TNCs $3,300 USD
LE005C 5 billion TNCs $5,300 USD
LE010C 10 billion TNCs $7,300 USD
-
+
Questions about shipping? See Shipping Info
Questions? Contact Sales:
530-303-3828
Contact Us
Product Description

Frozen Leukopaks® are collected from IRB consented healthy donors at our FDA-registered Stem Cell Collection Center. Using the Spectra Optia® Apheresis System, cell-rich peripheral blood mononuclear cells (PBMCs) are extracted using a continuous flow centrifugation system directly into a sterile collection bag containing the anticoagulant ACD-A. Besides the PBMCs, which consist of lymphocytes and monocytes, each Leukopak® will also contain minimal amounts of granulocytes and red blood cells.

The percentage of cells can vary from donor to donor. The following are average cell populations for a single donor Leukopak® prior to cryopreservation:

     • T cells - 55% (range 45-60%) 
     • Monocytes - 27% (range 10-30%)
     • B cells - 9% (5-15%)
     • NK cells - 8% (range 5-10%)
     • CD34+ stem cells - 0.1% (range 0.1-0.5%) 
     • Granulocytes - 2.3% (range 0.6-10%)
     • Hematocrit - 3% (range 2-3.5%)

Once collected, Leukopaks® are quickly frozen in a medium containing the cryoprotective agent CryoStorTM (10% DMSO) using a controlled rate freezer to ensure maximum viability. 

Total nucleated cell (TNC) counts and viability testing are performed prior to cryopreservation. For optimal cell recovery and viability, we recommend following our Thawing Protocol found under the Technical Resources tab. Deviations from this protocol can compromise viability and cell recovery.

For global shipments, we highly recommend shipping Frozen Leukopaks® in an LN2 cryoshipper to maintain proper temperatures for the duration of the transit time. Upon arrival, Frozen Leukopaks® should be stored in the vapor phase of liquid nitrogen or thawed immediately for use. 



Custom Orders

Design the right Leukopak® for your research needs. View our custom orders to see what options we have available.

More Information
Species Human
Disease State Healthy
Cell and Tissue Source Peripheral Blood
Product Type Whole
Cell Type Mononuclear Cells
Donor Attributes HIV-, HepB-, HepC-
Viability ≥95% by Flow Cytometry Prior to Cryopreservation
Format Frozen
Contains 10% DMSO
Anticoagulant ACD-A

Product Information Sheet

Certificate of Analysis

Material Safety Data Sheet

Protocols

  •  Leukopak Thawing Protocol - Video

Figure 1. Viability comparison, as determined by PI staining, of fresh and thawed Leukopaks®. Average viability of fresh Leukopaks® taken at the time of collection was 97.56% while the average post-thaw viability taken 7 days after cryopreservation was 96.33%.

Figure 1. Viability comparison, as determined by PI staining, of fresh and thawed Leukopaks®. Average viability of fresh Leukopaks® taken at the time of collection was 97.56% while the average post-thaw viability taken 7 days after cryopreservation was 96.33%.

Hi, have questions?

A StemExpress Expert is happy to help!

Call 530.303.3828 or Contact Us